Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• Analyst consensus: Nine brokerages rate Perspective Therapeutics as a "Buy" (eight Buy, one Strong Buy) with an average 12‑month target of about $12.63 and individual price targets ranging roughly from $11 to $16.
• Institutional backing: Institutional investors own 54.66% of the company, and several major firms (Vanguard, Avidity, Geode, State Street) recently increased or established stakes in CATX.
• Financial and stock snapshot: Shares trade around $4.25 with a 12‑month range of $1.75–$6.16; the company shows strong liquidity (quick/current ratio 5.17) but is unprofitable (Q1 EPS -$0.51, extremely negative net margin, and consensus FY EPS of about -$0.88).

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has earned an average rating of "Buy" from the nine brokerages that are covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $12.6250.

A number of research analysts recently issued reports on the company. Truist Financial set a $12.00 price objective on Perspective Therapeutics in a research report on Tuesday, March 17th. Piper Sandler assumed coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an "overweight" rating and a $16.00 price objective for the company. HC Wainwright boosted their price objective on Perspective Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Monday, March 23rd. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 18th. Finally, B. Riley Financial boosted their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, March 18th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CATX. Vanguard Group Inc. raised its stake in shares of Perspective Therapeutics by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company's stock worth $11,792,000 after buying an additional 163,532 shares in the last quarter. Avidity Partners Management LP raised its stake in shares of Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company's stock worth $8,830,000 after buying an additional 216,700 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company's stock worth $4,758,000 after buying an additional 188,887 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth $3,257,000. Finally, State Street Corp raised its stake in shares of Perspective Therapeutics by 3.3% in the 4th quarter. State Street Corp now owns 1,141,247 shares of the company's stock worth $3,138,000 after buying an additional 36,543 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $4.25 on Wednesday. Perspective Therapeutics has a 12 month low of $1.75 and a 12 month high of $6.16. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $4.81 and a two-hundred day moving average price of $3.56.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The company had revenue of $0.04 million for the quarter. On average, equities analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.